NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis → Radical change coming — do this NOW to protect yourself (From Weiss Ratings) (Ad) Free VNRX Stock Alerts $0.69 -0.02 (-2.68%) (As of 01:21 PM ET) Add Compare Share Share Today's Range$0.68▼$0.7350-Day Range$0.60▼$0.9152-Week Range$0.55▼$1.66Volume40,927 shsAverage Volume188,987 shsMarket Capitalization$57.06 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get VolitionRx alerts: Email Address VolitionRx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside264.9% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.84 out of 5 starsMedical Sector818th out of 913 stocksDiagnostic Substances Industry13th out of 14 stocks 3.5 Analyst's Opinion Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 1 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VNRX. Previous Next 0.0 Dividend Strength Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VNRX. Previous Next 1.8 News and Social Media Coverage News SentimentVolitionRx has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for VolitionRx this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have not sold or bought any company stock.Percentage Held by Insiders12.80% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -1.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsMassive Crisis Looming — Protect Your Savings NowToday, Dr. Weiss is coming forward with a new warning, Only this time, it's not about the stock market, inflation, or recession … This time, it's about your financial freedom.Click here to learn how to prepare before it's too late. About VolitionRx Stock (NYSE:VNRX)VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Read More VNRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VNRX Stock News HeadlinesJune 14 at 5:46 AM | americanbankingnews.comVolitionRx (NYSE:VNRX) Receives New Coverage from Analysts at StockNews.comMay 29, 2024 | prnewswire.comVolitionRx Limited to Present at Jefferies Global Healthcare ConferenceMay 15, 2024 | finance.yahoo.comVolitionRX Ltd (VNRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances and ...May 13, 2024 | washingtonpost.comVolitionRX: Q1 Earnings SnapshotMay 13, 2024 | prnewswire.comVolitionRx Limited Announces First Quarter 2024 Financial Results and Business UpdateMay 8, 2024 | prnewswire.comVolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business UpdateApril 8, 2024 | msn.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method ...April 8, 2024 | finance.yahoo.comVNRX: VolitionRx Reports 2023 Results; Distribution of Nu.Q Vet Test Expanding; Nu.Q Discover Growing; Two Key R&D Efforts in 2024/25: 1) Breakthrough Cancer Detection Method (Capture -PCR) 2) Nu.Q NET for SepsisMarch 25, 2024 | msn.comVNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023March 25, 2024 | prnewswire.comVolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business UpdateMarch 22, 2024 | benzinga.comEarnings Outlook For VolitionRXMarch 21, 2024 | prnewswire.comVolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business UpdateMarch 21, 2024 | finanznachrichten.deVolitionRx Limited: Volition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | markets.businessinsider.comVolitionRx Names Andrew Retter Chief Medical OfficerMarch 19, 2024 | finance.yahoo.comVolition appoints Dr Andrew Retter as Chief Medical OfficerMarch 19, 2024 | money.usnews.comVolitionRX LtdFebruary 22, 2024 | benzinga.comVolitionRX Stock (AMEX:VNRX), Short Interest ReportJanuary 2, 2024 | msn.comVolitionRx stock soars after company discloses $13M in milestone paymentsJanuary 2, 2024 | realmoney.thestreet.comVolitionRx milestone payment 'important step forward,' says EF HuttonNovember 17, 2023 | finance.yahoo.comVolition Presents at the 5th Annual Congress of the International Liquid Biopsy SocietyNovember 8, 2023 | proactiveinvestors.comVolitionRx to host Q3 earnings call on November 15October 28, 2023 | markets.businessinsider.comVolitionRX’s Innovative Cancer Detection Platform: A Promising Investment – An Analyst’s PerspectiveSee More Headlines Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:VNRX CUSIPN/A CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+253.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,320,000.00 Net Margins-4,379.67% Pretax Margin-4,426.10% Return on EquityN/A Return on Assets-150.15% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.43 Sales & Book Value Annual Sales$770,000.00 Price / Sales76.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-6.44Miscellaneous Outstanding Shares82,820,000Free Float72,223,000Market Cap$58.64 million OptionableOptionable Beta1.17 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Martin Charles Faulkes Ph.D. (Age 80)Executive Chairman Comp: $239.51kMr. Cameron Reynolds MBA (Age 53)Founder, CEO, President & Director Comp: $572.43kDr. Gaetan Michel Ph.D. (Age 50)Chief Operating Officer Comp: $518.15kDr. Salvatore Thomas Butera DVM (Age 72)Chief Executive Officer of Volition Veterinary Diagnostics Development LLC Comp: $477.25kMr. Terig Hughes (Age 53)CFO & Treasurer Comp: $338.74kDr. Jacob Vincent Micallef MBA (Age 68)Ph.D., Chief Scientific Officer Comp: $571.55kMr. Nicholas Plummer (Age 53)Group General Counsel Ms. Louise Batchelor Day (Age 52)Group Chief Marketing & Communications Officer Mr. Thomas BygottSales & Marketing DirectorMr. Gael Forterre M.B.A. (Age 42)Chief Commercial Officer More ExecutivesKey CompetitorsAchieve Life SciencesNASDAQ:ACHVAlpha TeknovaNASDAQ:TKNOARCA biopharmaNASDAQ:ABIOImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHView All CompetitorsInsidersCorp Ltd EightSold 20,000 sharesTotal: $18,000.00 ($0.90/share)Salvatore Thomas ButeraBought 10,000 shares on 12/18/2023Total: $8,300.00 ($0.83/share)Corp Ltd EightSold 20,000 sharesTotal: $15,000.00 ($0.75/share)Salvatore Thomas ButeraBought 10,000 shares on 12/15/2023Total: $7,700.00 ($0.77/share)Rodney Gerard RootsaertBought 10,000 shares on 12/13/2023Total: $6,000.00 ($0.60/share)View All Insider Transactions VNRX Stock Analysis - Frequently Asked Questions Should I buy or sell VolitionRx stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for VolitionRx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VNRX shares. View VNRX analyst ratings or view top-rated stocks. What is VolitionRx's stock price target for 2024? 1 brokerages have issued 12-month price targets for VolitionRx's shares. Their VNRX share price targets range from $2.50 to $2.50. On average, they predict the company's share price to reach $2.50 in the next year. This suggests a possible upside of 264.9% from the stock's current price. View analysts price targets for VNRX or view top-rated stocks among Wall Street analysts. How have VNRX shares performed in 2024? VolitionRx's stock was trading at $0.7170 at the beginning of 2024. Since then, VNRX stock has decreased by 4.4% and is now trading at $0.6852. View the best growth stocks for 2024 here. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings data on Monday, May, 13th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business earned $0.17 million during the quarter, compared to analyst estimates of $0.27 million. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VNRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | Sponsored"Trump Loophole" Beats InflationThe demise of the "petrodollar" appears imminent. And the implications for Americans could be dire.Colonial Metals | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.